This presentation includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as "anticipate," "expect," "plan," "could," "would," "may," "will," "believe," "estimate," "forecast," "goal," "project," "guidance," "plan," "potential" and other words of similar meaning, although not all forward-looking statements include these words. These forward-looking statements address various matters, including the Company's strategy, future operations, futur ...

Core Insights - NeoGenomics reported a total revenue of $727 million for full-year 2025, reflecting a 10% increase compared to 2024, with clinical revenue up 15% and non-clinical revenue down 24% [1][7] - The company achieved adjusted gross profit of $335 million, an increase of 8%, and adjusted EBITDA rose 9% to $43.4 million [1] - For Q4 2025, total revenue was $190 million, up 11% year-over-year, with clinical revenue growing 16% while non-clinical revenue declined over 25% [3][4] Financial Performance - Adjusted gross profit for Q4 increased by $5.8 million, or 7%, with adjusted EBITDA rising 10% to $13.4 million [2] - The company reported positive cash flow from operations of $5 million in 2025, with free cash flow improving by over 35% compared to 2024 [1] - Total test volumes rose 11% in Q4, and average unit price (AUP) increased by 5% [8] Strategic Initiatives - NeoGenomics is shifting focus from low-value, high-volume contracts to higher-value, therapy-guided testing, which is expected to drive AUP expansion [6][9] - The company launched five NGS products in 2023, contributing 22% of clinical revenue in Q4, with NGS revenue growing 23% year-over-year [10][11] - The launch of the PanTracer Pro and the commercial rollout of the MRD test RaDaR ST are key initiatives, although contributions from PanTracer LBx depend on reimbursement timing [5][13] Market Outlook - For 2026, NeoGenomics targets revenue between $793 million and $801 million, with adjusted EBITDA expected to be between $55 million and $57 million [18][20] - The company anticipates a growth cadence of approximately 10% year-over-year in Q1, tapering to 8%-9% in Q2, and slightly above 10% in Q4 [19] - Management expects continued modest erosion in the pharma business in 2026, with a potential return to growth in 2027 [22] Operational Developments - The company is consolidating its laboratory information management systems (LIMS) from eight systems to one, with benefits expected to emerge in 2026 and more pronounced impacts in 2027 and 2028 [21] - NeoGenomics is expanding its sales force, particularly targeting ENT physicians for HPV-negative head and neck cancer, with plans to add over 25 oncology sales specialists by Q3 [16]

Financial Data and Key Metrics Changes - Total revenue for Q4 2025 was $190 million, representing an 11% year-over-year growth [6] - Full year total revenue reached $727 million, a 10% increase over 2024 [24] - Adjusted gross profit improved by $5.8 million, or 7% over the prior year, with adjusted EBITDA at $13.4 million, up 10% [20] - Cash flow from operations was positive at $1 million for Q4, with total cash at $160 million [22] Business Line Data and Key Metrics Changes - Clinical business revenue increased by 16% year-over-year in Q4, driven by effective commercial strategies [6] - NGS revenue grew by 23% year-over-year, accounting for about one-third of total clinical revenue [21] - Non-clinical revenue declined by over 25% in Q4, with a full year decline of 24% [20][24] Market Data and Key Metrics Changes - The company holds a leadership position in the hematology testing market with over 25% market share [9] - Approximately 40% of active pathologists and oncologists ordered five or more tests from NeoGenomics during the year [10] Company Strategy and Development Direction - The company aims to drive growth through the expansion of NGS revenues and market penetration for the PanTracer family and RaDaR ST [29] - A focus on strategic, profitable growth is emphasized, with investments in sales and marketing and R&D for new product initiatives [28] - The company is preparing for a full clinical launch of the RaDaR ST MRD assay, which is expected to enhance market opportunities [12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving revenue guidance for 2026, expecting revenues between $793 million and $801 million [26] - The company anticipates modest revenue contributions from RaDaR ST in 2026, with growth expected to accelerate in 2027 and beyond [13] - Management acknowledged potential impacts from extreme weather on Q1 volumes but remains optimistic about overall growth [27] Other Important Information - The company has launched five NGS products since March 2023, contributing significantly to revenue growth [18] - The acquisition of PathLine is expected to provide operational efficiencies and synergies that will be accretive to profitability [10] Q&A Session Summary Question: Can you provide specifics on the RaDaR ST launch and sales rep focus? - Management confirmed the full launch of RaDaR ST is planned for the end of the month, focusing on head and neck and subsets of breast cancer [34] - The initial sales force expansion will target the head and neck market, with plans to add more reps for future indications [36] Question: What is the impact of exiting low-value business on clinical volume? - Management indicated that exiting low-value contracts will lead to higher AUPs and better margins, with expectations for AUP growth in the upper single-digit range [44] Question: Can you clarify guidance for the core clinical business? - Management expects the core clinical business to grow at about 10%, factoring in the full year of PathLine and the impact of exiting low-value contracts [52] Question: What is the framework for LIMS integration this year? - The company is migrating to a common LIMS system, with benefits expected to materialize in 2027, while optimizing workflows for efficiency [57] Question: What is the potential for continued ASP growth? - Continued growth in AUP is anticipated, driven by the shift into NGS and managed care pricing increases [84]

Q4 and FY 2025 Financial Results February 17, 2026 Nasdaq: NEO Safe Harbor Statements This presentation has been prepared by NeoGenomics, Inc. ("we," "us," "our," "NeoGenomics" or the "Company"). Statements contained herein are made as of the date of this presentation unless stated otherwise. This presentation includes forward-looking statements. These forward-looking statements generally can be identified by the use of words such as "anticipate," "expect," "plan," "could," "would," "may," "will," "believe, ...

Core Insights - NeoGenomics, Inc. has launched a new pan-solid tumor assay called PanTracer Pro, aimed at assisting clinicians in navigating complex molecular testing workflows for patients with advanced-stage solid tumors [1][2] - The company has reported a significant increase in its stock price, with shares rising 82.4% over the past six months, outperforming the industry and the S&P 500 Index [3] - NeoGenomics' revenues have shown a consistent upward trend, with a 36.6% increase from 2021 to 2024, and preliminary results for 2025 indicate a year-over-year sales growth of 10% to $727 million [4][5] Product Development - The PanTracer Pro assay is designed to streamline testing processes in precision oncology, combining DNA and RNA sequencing of over 500 cancer-related genes with tumor-specific ancillary testing [6][10] - This new assay aims to reduce diagnostic complexity and turnaround time, facilitating timely treatment decisions for cancer patients [2][10] - In cases where tissue samples are insufficient, clinicians can transition to the PanTracer LBx liquid biopsy assay without restarting the diagnostic process, thus avoiding delays in patient care [11] Financial Performance - NeoGenomics reported Q4 sales of approximately $190 million, reflecting an 11% increase year over year, and anticipates continued double-digit growth in 2026 [8][12] - The company expects ongoing top-line growth driven by the increasing adoption of precision oncology and its comprehensive suite of oncology tests [5][8] Market Position - The launch of PanTracer Pro is expected to enhance NeoGenomics' competitive position in the precision oncology market by addressing the challenges of fragmented testing workflows and supporting personalized treatment planning [9][10] - The company currently holds a Zacks Rank of 2 (Buy), indicating a favorable outlook compared to other stocks in the medical sector [13]

Core Insights - NeoGenomics has launched PanTracer Pro, a new integrated testing approach aimed at improving the selection of therapies for patients with advanced-stage solid tumors by providing earlier biomarker insights and reducing diagnostic uncertainty [1][2] Group 1: Product Features - PanTracer Pro integrates comprehensive genomic profiling (CGP) with diagnosis-directed immunohistochemistry (IHC) and ancillary testing tailored to tumor type, allowing for a more streamlined testing process [1] - The turnaround time for PanTracer Pro tests is 8–10 days, facilitating timely treatment decisions in real-world clinical settings [1] - The product aims to identify clinically relevant biomarkers that may be overlooked in incomplete testing, thus supporting therapy selection and personalized treatment planning [1] Group 2: Market Context - As precision oncology evolves, clinicians are facing increased complexity in diagnostics and biomarker requirements, necessitating quicker treatment initiation often before complete molecular profiles are available [1] - The fragmented nature of current testing workflows can lead to delays in patient care, which PanTracer Pro seeks to address by providing a coordinated testing approach [1] Group 3: Company Overview - NeoGenomics, Inc. is a leading provider of oncology diagnostic solutions, specializing in cancer genetics testing and information services, with a comprehensive testing menu serving various stakeholders in the oncology field [1]